The current dogma of G(1) cell-cycle progression relies on growth factor-induced increase of cyclin D:Cdk4/6 complex activity to partially inactivate pRb by phosphorylation and to sequester p27(Kip1)-triggering activation of cyclin E:Cdk2 complexes that further inactivate pRb. pRb oscillates between an active, hypophosphorylated form associated with E2F transcription factors in early G(1) phase and an inactive, hyperphosphorylated form in late G(1), S and G(2)/M phases. However, under constant growth factor stimulation, cells show constitutively active cyclin D:Cdk4/6 throughout the cell cycle and thereby exclude cyclin D:Cdk4/6 inactivation of pRb. To address this paradox, we developed a mathematical model of G(1) progression using physiological expression and activity profiles from synchronized cells exposed to constant growth factors and included a metabolically responsive, activating modifier of cyclin E:Cdk2. Our mathematical model accurately simulates G(1) progression, recapitulates observations from targeted gene deletion studies and serves as a foundation for development of therapeutics targeting G(1) cell-cycle progression.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1828753PMC
http://dx.doi.org/10.1038/msb4100126DOI Listing

Publication Analysis

Top Keywords

cyclin dcdk4/6
12
cell cycle
8
cell-cycle progression
8
inactivate prb
8
cyclin ecdk2
8
constant growth
8
mathematical model
8
progression
5
cyclin
5
systems biology
4

Similar Publications

Objective: The data on the association between phthalates and breast cancer risk remains inconsistent. This study aimed to explore the possible mechanism of low-dose exposures of phthalates, including Butyl benzyl phthalate (BBP), di(n-butyl) phthalate (DBP), and di(20ethylhexyl) phthalate (DEHP), on breast tumorigenesis.

Methods And Methods: MCF-10A normal breast cells were treated with phthalates (10 and 100 nM) and 17β-estradiol (E, 10 nM), which were co-cultured with fibroblasts from normal mammary tissue.

View Article and Find Full Text PDF

The combination of cyclin-dependent kinase (CDK) 4/6 inhibitors with endocrine therapy is the standard treatment for patients with HR+/HER2- advanced breast cancer. Recently, this combination has also entered the early setting as an adjuvant treatment in patients with HR+/HER2- disease at a high risk of disease recurrence following (neo)adjuvant chemotherapy. Despite their current use in clinical practice, limited data on the potential gonadotoxicity of CDK4/6 inhibitors are available.

View Article and Find Full Text PDF

Molecular and clinical diversity in primary central nervous system lymphoma.

Ann Oncol

February 2023

Institut du Cerveau-Paris Brain Institute-ICM, Inserm, Sorbonne Université, CNRS, Paris, France; Department of Neurology-2, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière-Charles Foix, Paris, France. Electronic address:

Article Synopsis
  • Primary central nervous system lymphoma (PCNSL) is a unique type of diffuse large B-cell lymphoma that shows varied response rates likely due to its molecular complexity.
  • A detailed analysis of 147 fresh-frozen and 93 formalin-fixed PCNSLs identified four significant prognostic clusters, with distinct clinical behaviors and genetic profiles.
  • The findings suggest targeted therapeutic approaches for each PCNSL subtype, including immune checkpoint inhibitors and various targeted drugs based on their specific molecular characteristics.
View Article and Find Full Text PDF

The cyclin-dependent kinase (CDK) inhibitor p27 regulates cell proliferation. Phosphorylation of tyrosine residue 88 (Y88) converts the inhibitor into an assembly factor and activator of CDKs, since Y88-phosphorylation restores activity to cyclin E,A/CDK2 and enables assembly of active cyclin D/CDK4,6. To investigate the physiological significance of p27 tyrosine phosphorylation, we have generated a knock-in mouse model where Y88 was replaced by phenylalanine (p27-Y88F).

View Article and Find Full Text PDF

Cyclin-dependent kinase 4 (CDK4) is a master integrator that couples mitogenic/oncogenic signaling with the cell division cycle. It is deregulated in most cancers and inhibitors of CDK4 have become standard of care drugs for metastatic estrogen-receptor positive breast cancers and are being evaluated in a variety of other cancers. We previously characterized the T-loop phosphorylation at T172 of CDK4 as the highly regulated step that determines the activity of cyclin D-CDK4 complexes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!